ANTEJIN BIOTECH
Antejin Biotech specializes in developing rabies immunogenic conjugate useful for preparing rabies conjugate vaccine.
ANTEJIN BIOTECH
Industry:
Biotechnology
Address:
Chengdu, Sichuan, China
Country:
China
Status:
Active
Similar Organizations
Oligogen
Oligogen is a bio-venture that specializes in drug development using stem cell technology.
More informations about "Antejin Biotech"
Fosun Pharma acquires Antejin Biotech - 2021-10-28 - Crunchbase
Acquired Organization: Antejin Biotech Antejin Biotech specializes in developing rabies immunogenic conjugate useful for preparing rabies conjugate vaccine. Acquiring Organization: …See details»
Fosun Pharma acquires vaccine firm Antejin in deal worth up
Nov 2, 2021 Fosun Pharmaceutical Group Co. Ltd. has acquired a 73% stake of Antejin Biotech Co. Ltd. in a merger and acquisition deal worth up to ¥4.006 billion (US$626.2 million) to …See details»
Antejin Biotech Co Ltd - Drug pipelines, Patents, Clinical trials
Explore Antejin Biotech Co Ltd with its drug pipeline, therapeutic area, technology platform, . Data. Feature. Plans. Sign Up for Free. Request Demo. Sign Up for Free. Last update 02 May …See details»
Chengdu Antejin Biotech Co. - PitchBook
Chengdu Antejin Biotech Co. General Information Description. Developer of vaccines based in Chengdu, China. The company specializes in developing rabies immunogenic conjugate …See details»
Chengdu Antejin Biotech - Products, Competitors, Financials, …
Chengdu Antejin Biotech is a biotechnology company that produces pneumonia, tetanus, rabies, and other vaccines. It is based in Chengdu, Sichuan. On October 28th, 2021, Fosun …See details»
Antejin Biotech - Company Profile - Tracxn
Oct 21, 2024 Antejin Biotech - Provider of bacterial vaccine development and pharmaceutical services. Acquired by Fosun Pharmaceutical. Antejin Biotech has 36 competitors.See details»
Fosun Pharma acquires vaccine firm Antejin in deal worth up to …
Fosun Pharmaceutical Group Co. Ltd. has acquired a 73% stake of Antejin Biotech Co. Ltd. in a merger and acquisition deal worth up to ¥4.006 billion (US$626.2 million) to expand its pipeline …See details»
Fosun Announces $628 Million Deal for Majority Stake in Chengdu …
Oct 27, 2021 Shanghai Fosun Pharma announced a $628 million deal to acquire a 73% stake in Chengdu Antejin Biotech, a vaccine company. Fosun paid $174 million to nine Antejin …See details»
Antejin Biotech - Crunchbase
Antejin Biotech specializes in developing rabies immunogenic conjugate useful for preparing rabies conjugate vaccine.See details»
Week In Review: Fosun Pharma Acquires Majority Stake In China …
Image Source: Unsplash Deals and Financings. Shanghai Fosun Pharma announced a $628 million deal to acquire a 73% stake in Chengdu Antejin Biotech, a vaccine company (see …See details»
Antejin Biotech Co. Ltd. | BioWorld
Aug 27, 2024 Fosun Pharmaceutical Group Co. Ltd. has acquired a 73% stake of Antejin Biotech Co. Ltd. in a merger and acquisition deal worth up to ¥4.006 billion (US$626.2 million) …See details»
Fosun Announces $628 Million Deal for Majority Stake in Chengdu …
On October 27, 2021 Shanghai Fosun Pharma reported a $628 million deal to acquire a 73% stake in Chengdu Antejin Biotech, a vaccine company (Press release, Fosun Pharma, OCT …See details»
Week in review: Fosun Pharma acquires majority stake in China …
Nov 1, 2021 Deals and Financings. Shanghai Fosun Pharma (OTCPK:SFOSF, SHA: 600196, HK: 02196) announced a $628 million deal to acquire a 73% stake in Chengdu Antejin …See details»
Fosun Antejin - PitchBook
Fosun Antejin was founded in 2012. Where is Fosun Antejin headquartered? Fosun Antejin is headquartered in Chengdu, China. What is the size of Fosun Antejin? Fosun Antejin has 600 …See details»
Chengdu Antejin Biotech Stock Price, Funding, Valuation, Revenue ...
See Chengdu Antejin Biotech funding rounds, investors, investments, exits and more. Evaluate their financials based on Chengdu Antejin Biotech's post-money valuation and revenue. …See details»
Week in Review: Fosun Pharma Acquires Majority Stake in China …
Oct 30, 2021 Deals and Financings Shanghai Fosun Pharma will buy a 73% stake in Chengdu Antejin Biotech, a vaccine company, for $628 million -- $174 million in cash plus its vaccine …See details»
Antejin Biotech - 30 Competitors and Alternatives - Tracxn
Antejin Biotech has 30 active competitors. Competitors include RadiologyInfo, PharmaReview.See details»
23-valent pneumococcal polysaccharide vaccine (Chengdu Antejin)
23-valent pneumococcal polysaccharide vaccine (Chengdu Antejin): a Immunostimulants Drug, Initially developed by Chengdu Antejin Biotechnology Co., Ltd., Now, its global highest R&D …See details»
13-valent pneumococcal conjugate vaccine(Fosun Adgenvax
Chengdu Antejin Biotechnology Co., Ltd. ChiCTR2300077384 / Recruiting Phase 3 IIT Phase III clinical trial to evaluate the immunogenicity and safety of 13-valent pneumococcal conjugate …See details»